Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United
States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum Therapeutics plc was founded in 2015 and is headquartered in Dublin, Ireland. The company trades on NASDAQ exchange. The company headquarter is located in Dublin, . The company was established in the 2015.
| Ticker | ITRM |
| Long Name | Iterum Therapeutics plc |
| Short Name | Iterum Therapeutics |